Generated by All in One SEO Pro v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# BioModels

## Sitemaps

- [XML Sitemap](https://biomodels.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Representative Data Module 1](https://biomodels.com/representative-data-module-1/) - Representative Data Model 1Click Image to EnlargePercent Weight Change in the Murine DSS Colitis ModelDSS-induced animals are weighed daily, and body weight change as compared to Day 0 is calculated. The AUC is calculated to compare treatment arms and is shown in the inset. (**p

## Pages

- [Homepage](https://biomodels.com/) - BioModels, a Boston-based preclinical CRO, provides cutting edge research services, with the expertise to advance your novel therapeutics to the clinic
- [Our Team](https://biomodels.com/our-team/) - Our dynamic team is comprised of experienced clinicians and scientists who bring unique and deep expertise to support your preclinical research program
- [Events](https://biomodels.com/events/) - Find out where to join BioModels at our upcoming events and conferences. We look forward to meeting you there!
- [Compliance/Regulatory](https://biomodels.com/compliance-regulatory/) - RESOURCE CENTER Compliance/RegulatoryAccreditations and LicensesAAALAC AccreditedOLAW Assured USDA Registered DEA LicensedMCSR LicensedComplianceBioModels is committed to the ethical and responsible use of animals in research and follows all US federal laws and regulations. BioModels’ complies with The Guide for the Care and Use of Laboratory Animals and adheres to its principles and standards for animal research.
- [Gene Therapy and RNA](https://biomodels.com/gene-therapy-and-rna/) - BioModels is a Boston-based preclinical CRO that has extensive experience with a variety of gene therapy and mRNA vaccine approaches.
- [Histopathology](https://biomodels.com/histopathology/) - Capabilities Histopathology Histopathology Paired with clinical endpoints, histopathology provides comprehensive insight for model characterization and therapeutic efficacy as you progress through the drug discovery pipeline. We offer seamless integration of these critical endpoints through our collaboration with the experts at DTR Labs. The team at DTR provides non-clinical, non-GLP histology services guided by ACVP-board certified
- [In-Life Monitoring](https://biomodels.com/in-life-monitoring/) - Support your preclinical studies with endoscopy, IVIS, DEXA, body temperature, behavioral assessments, grip strength and more at BioModels, a Boston-based CRO
- [Preclinical Contract Research Services](https://biomodels.com/preclinical-contract-research-services/) - BioModels is a Boston-based preclinical contract research organization that specializes in the development and execution of efficacy studies in mouse and rat disease models. As an integral part of the drug development process, we are here to evaluate your test articles utilizing the most clinically translational models available. Explore our therapeutic areas below or contact
- [Partner with PES- Clinical Endpoint Experts](https://biomodels.com/partner-with-pes-clinical-endpoint-experts/)
- [Grant Support and Consulting](https://biomodels.com/grant-support-and-consulting-2/)
- [Microbiome Contract Research](https://biomodels.com/microbiome-research/) - Evaluate your microbiome products and targets using microbiology and germ-free/gnotobiotic modeling expertise at BioModels, a Boston-based preclinical CRO
- [How We Work](https://biomodels.com/how-we-work/) - BioModels’ collaborative approach integrates your preclinical project needs and our expertise to provide a start-to-finish solution that yields actionable data
- [Our Company](https://biomodels.com/our-company/) - ABOUT US Our Company Personalized Service We view our clients as collaborators rather than customers. The result is an active engagement in personal service and scientific discussions to develop and execute your studies. At BioModels, you will work with a PhD level scientist who is an expert in your selected disease indication. Your scientific partner
- [Cardiovascular and Additional Models](https://biomodels.com/cardiovascular-and-additional-models/) - Cardiovascular and Additional Models Cardiovascular and Additional Models BioModels offers customized solutions for clients working in disease areas that may lack readily standardized models, as well as disease areas that are a bit less mainstream, representing niche areas of inquiry. This work has resulted in the establishment of preclinical rodent models for thrombosis, blood pressure
- [Neuroscience](https://biomodels.com/neuroscience/) - Evaluate materials for efficacy and behavioral outcomes in models of Parkinson’s disease, depression, and autism at BioModels, a Boston-based preclinical CRO
- [Radiation Countermeasures - ARS](https://biomodels.com/radiation-countermeasures-ars/)
- [News](https://biomodels.com/news/) - Check out what’s new at BioModels! Explore upcoming events, data presentations, new science and more!
- [Webinars](https://biomodels.com/webinars/) - Explore BioModels expansive library of scientific webinars focusing on our highly translational preclinical research models. Review study designs, data & more!
- [All Publications](https://biomodels.com/publications/) - BioModels frequently collaborates with our partnersto publish high impact and cutting-edge translational research across numerous disease indications
- [Our History](https://biomodels.com/our-history/) - BioModels was founded in 1997 as a preclinical CRO to provide biotech/pharma with highly translational disease models, expediting their path to the clinic
- [Your Mission Critical Science Partner](https://biomodels.com/your-mission-critical-science-partner/) - BioModels is a preclinical CRO focused on a collaborative commitment to breakthrough science. We provide good science, high standards and quality data
- [Surgery](https://biomodels.com/surgery/) - Utilize our rodent surgical capabilities encompassing cecal cannulation, ALZET® osmotic pumps, UUO and custom surgical models at BioModels, a Boston-based CRO
- [Microbiology & Microbiome Capabilities](https://biomodels.com/microbiology-microbiome-capabilities/) - Support your preclinical program with germ-free/gnotobiotic vivarium, BSL-2 aerobic and anaerobic bacteria culture and more at BioModels, a Boston-based CRO
- [In Vitro and Ex Vivo Capabilities](https://biomodels.com/in-vitro-and-ex-vivo-capabilities/) - Support your preclinical projects with flow cytometry, multiplex cytokine analysis, qRT-PCR, serum chemistry, CBC and more at BioModels, a Boston-based CRO
- [PK/PD and Toxicology](https://biomodels.com/pk-pd-and-toxicology/) - Evaluate the PK/PD and non-GLP toxicology/tolerability profiles of your experimental materials at BioModels, a Boston-based preclinical CRO
- [Pulmonary Disease](https://biomodels.com/pulmonary-disease/) - Evaluate materials for efficacy and MOA in models of asthma, acute lung injury (ARDS/COPD), pulmonary fibrosis, at BioModels, a Boston-based preclinical CRO
- [Metabolic Disease](https://biomodels.com/metabolic-disease/) - Evaluate materials for efficacy and MOA in models of obesity, diabetes, NASH, and diabetic wound healing at BioModels, a Boston-based preclinical CRO
- [Oncology Models](https://biomodels.com/oncology-models/) - Evaluate materials for efficacy and MOA in established and customizable syngeneic and xenograft tumor models at BioModels, a Boston-based preclinical CRO
- [Fibrosis](https://biomodels.com/fibrosis/) - Evaluate materials for efficacy and MOA in models of pulmonary, liver, dermal, renal and systemic fibrosis at BioModels, a Boston-based preclinical CRO
- [Cancer Supportive Care](https://biomodels.com/cancer-supportive-care/) - Evaluate experimental materials for efficacy in models of oral or GI mucositis, CID, proctitis, dermatitis and more at BioModels, a Boston-based preclinical CRO
- [Inflammatory & Immune Mediated Diseases](https://biomodels.com/inflammatory-immune-mediated-diseases/) - Evaluate materials for efficacy and MOA in preclinical animal models of IBD, GVHD, RA, EAE and other inflammatory diseases at BioModels, a Boston-based CRO
- [Immunogenicity and Infectious Disease](https://biomodels.com/immunogenicity-and-infectious-disease/) - Evaluate experimental materials for their immunogenicity (vaccines) or assess their efficacy in infectious disease at BioModels, a Boston-based preclinical CRO
- [Inflammatory and Immune Mediated Diseases](https://biomodels.com/inflammatory-and-immune-mediated-diseases/)
- [Results](https://biomodels.com/results/)
- [](https://biomodels.com/privacy-policy/) - Privacy PolicyBioModels, LLC is committed to protecting your privacy and making it easier and more efficient for you to interact with us. We recognize it is essential for you to be confident that your privacy is protected when you visit our website, use our services, and communicate with us.Your privacy is important to you and
- [Disease Area](https://biomodels.com/disease-area/)
- [Sample Page](https://biomodels.com/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

## Publications

- [The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis](https://biomodels.com/publication/the-path-to-an-evidence-based-treatment-protocol-for-extraoral-photobiomodulation-therapy-for-the-prevention-of-oral-mucositis-2/) - Abstract: Oral Mucositis is a painful complication of hematopoietic stem cell transplantation for which photobiomodulation therapy (PBMT) is a safe and effective intervention. Extraoral delivery of PBMT has clinical advantages over intraoral delivery but requires additional dosimetric considerations due to the external tissue layers through which the light must propagate before reaching the oral mucosa.
- [Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges](https://biomodels.com/publication/predicting-mucositis-risk-associated-with-cytotoxic-cancer-treatment-regimens-rationale-complexity-and-challenges/) - Purpose of Review: The goals of this review are to describe the complexity of factors influencing the risk of cancer regimen-related mucosal injury (CRRMI), to evaluate the contribution of the innate immune response to CRRMI risk, to compare the concordance of genome analytics in describing mechanism and risk, and to determine if common biological pathways
- [New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury](https://biomodels.com/publication/new-frontiers-in-the-pathobiology-and-treatment-of-cancer-regimen-related-mucosal-injury/) - Abstract: Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have
- [Dusquetide: Reduction in Oral Mucositis Associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients](https://biomodels.com/publication/dusquetide-reduction-in-oral-mucositis-associated-with-enduring-ancillary-benefits-in-tumor-resolution-and-decreased-mortality-in-head-and-neck-cancer-patients/) - Abstract: Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for
- [Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients](https://biomodels.com/publication/exploring-genetic-attributions-underlying-radiotherapy-induced-fatigue-in-prostate-cancer-patients/) - Abstract: CONTEXT: Despite numerous proposed mechanisms, no definitive pathophysiology underlying radiotherapy-induced fatigue (RIF) has been established. However, the dysregulation of a set of 35 genes was recently validated to predict development of fatigue in prostate cancer patients receiving radiotherapy. OBJECTIVES: To hypothesize novel pathways, and provide genetic targets for currently proposed pathways implicated in RIF
- [On the Pathogenesis of mTOR Inhibitor-Associated Stomatitis (mIAS)-Studies using an Organotypic Model of the Oral Mucosa](https://biomodels.com/publication/on-the-pathogenesis-of-mtor-inhibitor-associated-stomatitis-mias-studies-using-an-organotypic-model-of-the-oral-mucosa/) - Abstract: OBJECTIVE: mTOR inhibitor treatment of solid cancers is associated with mTOR inhibitor-associated stomatitis (mIAS) a common, significant, dose-limiting toxicity, with aphthous-like lesions. Our objective was to assess the utility of a new organotypic model in defining mIAS’ pathogenesis. MATERIALS AND METHODS: The effect of everolimus on organotypic human oral mucosa was studied. Sterile specimens
- [Genomic Data Integration in Chronic Lymphocytic Leukemia](https://biomodels.com/publication/genomic-data-integration-in-chronic-lymphocytic-leukemia/) - Abstract: BACKGROUND: B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous disease and the most common adult leukemia in western countries. IgVH mutational status distinguishes two major types of CLL, each associated with a different prognosis and survival. Sequencing identified NOTCH1 and SF3B1 as the two main recurrent mutations. We described a novel method to clarify
- [Impact of a Planned Dose Interruption of Dacomitinib in the Treatment of Advanced Non-Small-Cell Lung Cancer (ARCHER 1042)](https://biomodels.com/publication/impact-of-a-planned-dose-interruption-of-dacomitinib-in-the-treatment-of-advanced-non-small-cell-lung-cancer-archer-1042/) - Abstract: OBJECTIVES: Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the ARCHER 1042 study. MATERIALS AND METHODS: Patients, treatment-naïve for advanced NSCLC with EGFR activating mutations,
- [The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis during Radiation Therapy](https://biomodels.com/publication/the-chicken-or-the-egg-changes-in-oral-microbiota-as-cause-or-consequence-of-mucositis-during-radiation-therapy/) - Abstract: Oral mucositis remains one of the most dominant, serious, disruptive, and symptomatic complications of radiation therapy used for the treatment of cancers of the head and neck (Villa and Sonis, 2015). Progressive mucosal injury accompanies increasing daily radiation fractions until confluent, deep, ulceration develops in the majority of patients, and the lack of an
- [Impact of Microarray Preprocessing Techniques in Unraveling Biological Pathways](https://biomodels.com/publication/impact-of-microarray-preprocessing-techniques-in-unraveling-biological-pathways/) - Abstract: To better understand the impact of microarray preprocessing normalization techniques on the analysis of biological pathways in the prediction of chronic fatigue (CF) following radiation therapy, this study has compared the list of predictive genes found using the Robust Multiarray Averaging (RMA) and the Affymetrix MAS5 method, with the list that is obtained working
- [Toxicities Associated with Head and Neck Cancer Treatment and Oncology-Related Clinical Trials](https://biomodels.com/publication/toxicities-associated-with-head-and-neck-cancer-treatment-and-oncology-related-clinical-trials/) - Abstract: Approximately 600,000 new cases of head and neck cancer (HNC) would be diagnosed worldwide this year. Of those, a bit less than 10% would occur in the United States. Most of these neoplasms would be histologically diagnosed as a squamous cell carcinomas for which the preferred treatment typically consists of a multimodality approach that
- [Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study](https://biomodels.com/publication/dusquetide-a-novel-innate-defense-regulator-demonstrating-a-significant-and-consistent-reduction-in-the-duration-of-oral-mucositis-in-preclinical-data-and-a-randomized-placebo-controlled-phase-2a-cl/) - Abstract: Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection. Innate immunity has also been implicated in the pathogenesis of oral mucositis (OM), a universal toxicity of chemoradiation therapy (CRT).
- [Sensitivity Analysis of Gene Ranking Methods in Phenotype Prediction](https://biomodels.com/publication/sensitivity-analysis-of-gene-ranking-methods-in-phenotype-prediction/) - Abstract: INTRODUCTION: It has become clear that noise generated during the assay and analytical processes has the ability to disrupt accurate interpretation of genomic studies. Not only does such noise impact the scientific validity and costs of studies, but when assessed in the context of clinically translatable indications such as phenotype prediction, it can lead
- [Ultrasound-Mediated Drug Delivery](https://biomodels.com/publication/ultrasound-mediated-drug-delivery/) - Abstract: For patients with ulcerative colitis, the most common form of inflammatory bowel disease (IBD), aminosalicylates such as mesalamine provide first-line anti-inflammatory therapy. As efficacy is related to tissue concentration, when administered as a rectal enema, lack of retention challenges topical formulation effectiveness. To address this problem, Schoellhammer and his colleagues (Wu et al, 2015)
- [A Phase II Study (ARCHER 1042) to Evaluate Prophylactic Treatment of Dacomitinib-Induced Dermatologic and Gastrointestinal Adverse Events in Advanced Non-Small-Cell Lung Cancer](https://biomodels.com/publication/a-phase-ii-study-archer-1042-to-evaluate-prophylactic-treatment-of-dacomitinib-induced-dermatologic-and-gastrointestinal-adverse-events-in-advanced-non-small-cell-lung-cancer/) - Abstract: BACKGROUND: ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC treated
- [Cytokine-Mediated Blood Brain Barrier Disruption as a Conduit for Cancer/Chemotherapy-Associated Neurotoxicity and Cognitive Dysfunction](https://biomodels.com/publication/cytokine-mediated-blood-brain-barrier-disruption-as-a-conduit-for-cancer-chemotherapy-associated-neurotoxicity-and-cognitive-dysfunction/) - Abstract: Neurotoxicity is a common side effect of chemotherapy treatment, with unclear molecular mechanisms. Clinical studies suggest that the most frequent neurotoxic adverse events affect memory and learning, attention, concentration, processing speeds and executive function. Emerging preclinical research points toward direct cellular toxicity and induction of neuroinflammation as key drivers of neurotoxicity and subsequent cognitive
- [Pharmacotherapy for the Management of Cancer Regimen-Related Oral Mucositis](https://biomodels.com/publication/pharmacotherapy-for-the-management-of-cancer-regimen-related-oral-mucositis/) - Abstract: INTRODUCTION: Oral mucositis is a frequent and devastating toxicity secondary to cancer treatment, which may affect 20-40% of patients receiving conventional chemotherapy and 60-85% of patients undergoing hematopoietic stem cell transplantation. The pathobiology of mucositis includes a complex cascade of biologic events in which pro-inflammatory cytokines, ROS, second messengers, and the oral microbiome contribute
- [Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease](https://biomodels.com/publication/mammalian-target-of-rapamycin-inhibitor-associated-stomatitis-in-hematopoietic-stem-cell-transplantation-patients-receiving-sirolimus-prophylaxis-for-graft-versus-host-disease/) - Abstract: The mammalian target of rapamycin (mTOR) inhibitor sirolimus is effective in reducing incidence of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Agents that inhibit the mTOR pathway are known to be associated with significant and potentially dose-limiting toxicities, including stomatitis. The objective of this study was to report the clinical features
- [Supervised Classification by Filter Methods and Recursive Feature Elimination Predicts Risk of Radiotherapy-Related Fatigue in Patients with Prostate Cancer](https://biomodels.com/publication/supervised-classification-by-filter-methods-and-recursive-feature-elimination-predicts-risk-of-radiotherapy-related-fatigue-in-patients-with-prostate-cancer/) - Abstract: BACKGROUND: Fatigue is a common side effect of cancer (CA) treatment. We used a novel analytical method to identify and validate a specific gene cluster that is predictive of fatigue risk in prostate cancer patients (PCP) treated with radiotherapy (RT). METHODS: A total of 44 PCP were categorized into high-fatigue (HF) and low-fatigue (LF)
- [Mucositis: Pathobiology and Management](https://biomodels.com/publication/mucositis-pathobiology-and-management/) - Abstract: PURPOSE OF REVIEW: Oral mucositis remains a frequent debilitating toxicity associated with drug and radiation regimens used to treat cancer. This review highlights the recent understanding of the biological basis, risk factors for, and management for oral mucositis. RECENT FINDINGS: Prevalence and incidence data for mucositis are inconsistent and often underreported. The pathogenesis of
- [Genomics, Personalized Medicine, and Supportive Cancer Care](https://biomodels.com/publication/genomics-personalized-medicine-and-supportive-cancer-care/) - Abstract: The successes of the Human Genome Project catalyzed the transition of genomics from the laboratory to the clinic. Over the past decade, there has been a proliferation of studies demonstrating the potential utility of various applications of genomics as a conduit to accelerate drug development, understand mechanism(s) of action, and personalize treatment. For patients
- [Risk and Outcomes of Chemotherapy-Induced Diarrhea (CID) among Patients with Colorectal Cancer Receiving Multi-Cycle Chemotherapy](https://biomodels.com/publication/risk-and-outcomes-of-chemotherapy-induced-diarrhea-cid-among-patients-with-colorectal-cancer-receiving-multi-cycle-chemotherapy/) - Abstract: BACKGROUND: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients
- [Emerging Therapies for the Prevention and Treatment of Oral Mucositis](https://biomodels.com/publication/emerging-therapies-for-the-prevention-and-treatment-of-oral-mucositis/) - Abstract: INTRODUCTION: Oral mucositis remains a common, symptomatically devastating toxicity of common drug and radiation regimens used to treat cancer. The current limited treatment options are likely to be supplemented by an active pipeline in which innovative compounds are being developed which target the underlying biological pathways associated with the condition. AREAS COVERED: A systematic
- [Unanticipated Frequency and Consequences of Regimen-Related Diarrhea in Patients Being Treated with Radiation or Chemoradiation Regimens for Cancers of the Head and Neck or Lung](https://biomodels.com/publication/unanticipated-frequency-and-consequences-of-regimen-related-diarrhea-in-patients-being-treated-with-radiation-or-chemoradiation-regimens-for-cancers-of-the-head-and-neck-or-lung/) - Abstract: PURPOSE: To better understand the indirect effects of standard courses of radiation therapy (RT) on distant tissue toxicity, we evaluated the frequency, course, and health and economic burden of regimen-related diarrhea in a large, multinational group of patients who were being treated for cancers of the head and neck (HNC) or lung (NSCLC). METHODS:
- [Randomized Double-Blind Placebo-Controlled Trial of Celecoxib for Oral Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer](https://biomodels.com/publication/randomized-double-blind-placebo-controlled-trial-of-celecoxib-for-oral-mucositis-in-patients-receiving-radiation-therapy-for-head-and-neck-cancer/) - Abstract: OBJECTIVES: Oral mucositis (OM) is a painful complication of radiation therapy (RT) for head and neck cancer (H&NC). OM can compromise nutrition, require opioid analgesics and hospitalization for pain control, and lead to treatment interruptions. Based on the role of inflammatory pathways in OM pathogenesis, we investigated effect of cyclooxygenase-2 (COX-2) inhibition on severity
- [New Frontiers in Mucositis](https://biomodels.com/publication/new-frontiers-in-mucositis/) - Abstract: Mucositis is among the most debilitating side effects of radiotherapy, chemotherapy, and targeted anticancer therapy. Research continues to escalate regarding key issues such as etiopathology, incidence and severity across different mucosae, relationships between mucosal and nonmucosal toxicities, and risk factors. This approach is being translated into enhanced management strategies. Recent technology advances provide an
- [MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy](https://biomodels.com/publication/mascc-isoo-clinical-practice-guidelines-for-the-management-of-mucositis-secondary-to-cancer-therapy/) - Abstract: BACKGROUND: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. METHODS: A literature search was conducted to identify eligible published articles, based
- [Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated with Chemoradiation Therapy for Cancers of the Head and Neck](https://biomodels.com/publication/multi-institutional-randomized-double-blind-placebo-controlled-trial-to-assess-the-efficacy-of-a-mucoadhesive-hydrogel-mugard-in-mitigating-oral-mucositis-symptoms-in-patients-being-treated-with/) - Abstract: BACKGROUND: The objective of this trial was to determine how a mucoadhesive hydrogel (MuGard), a marketed medical device, would fare when tested with the strictness of a conventional multi-institutional, double-blind, randomized, placebo-controlled study format. METHODS: A total of 120 subjects planned to receive chemoradiation therapy (CRT) for treatment of head and neck cancers were
- [Preliminary Characterization of Oral Lesions associated with Inhibitors of Mammalian Target of Rapamycin in Cancer Patients](https://biomodels.com/publication/preliminary-characterization-of-oral-lesions-associated-with-inhibitors-of-mammalian-target-of-rapamycin-in-cancer-patients/) - Abstract: BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors may have efficacy as an intervention for advanced malignancies. Oral ulceration (OU), reported as mucositis, has been a dose-limiting toxicity for this new class of agents. An analysis of the appearance, course, and toxicity associations of mTOR inhibitor-associated stomatitis (mIAS) demonstrated that the condition is distinct from
- [Attenuation of Radiation- and Chemoradiation-induced Mucositis using Gamma-D-glutamyl-L-tryptophan (SCV-07)](https://biomodels.com/publication/attenuation-of-radiation-and-chemoradiation-induced-mucositis-using-gamma-d-glutamyl-l-tryptophan-scv-07/) - Abstract: OBJECTIVE: To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced mucositis in an established animal model of oral mucositis (OM). MATERIAL AND METHODS: In three separate experiments, golden Syrian hamsters received either an acute radiation challenge to the buccal mucosa of eight fractionated doses of 7.5 Gy
- [Host-Microbiome Cross-Talk in Oral Mucositis](https://biomodels.com/publication/host-microbiome-cross-talk-in-oral-mucositis/) - Abstract: Oral mucositis (OM) is among the most common, painful, and debilitating toxicities of cancer regimen-related treatment, resulting in the formation of ulcers, which are susceptible to increased colonization of microorganisms. Novel discoveries in OM have focused on understanding the host-microbial interactions, because current pathways have shown that major virulence factors from microorganisms have the
- [Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients with Oral Cavity or Oropharyngeal Carcinoma](https://biomodels.com/publication/phase-1b-2a-trial-of-the-superoxide-dismutase-mimetic-gc4419-to-reduce-chemoradiotherapy-induced-oral-mucositis-in-patients-with-oral-cavity-or-oropharyngeal-carcinoma/) - Abstract: PURPOSE: To assess the safety of the superoxide dismutase mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal cancer (OCC) and to assess the potential of GC4419 to reduce severe oral mucositis (OM). PATIENTS AND METHODS: Patients with locally advanced OCC treated with definitive or postoperative intensity
- [Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis](https://biomodels.com/publication/topical-application-of-the-synthetic-triterpenoid-rta-408-protects-mice-from-radiation-induced-dermatitis/) - Abstract: Free radicals produced during cancer radiotherapy often leads to dermatitis, with the insult ranging from mild erythema to moist desquamation and ulceration. This toxicity can be dose limiting and promote chronic complications, such as fibrosis and wound recurrence. The purpose of this study was to evaluate if RTA 408, a synthetic triterpenoid that potently
- [Toll-Like Receptor 4 Signaling: A Common Biological Mechanism of Regimen-Related Toxicities: An Emerging Hypothesis for Neuropathy and Gastrointestinal Toxicity](https://biomodels.com/publication/toll-like-receptor-4-signaling-a-common-biological-mechanism-of-regimen-related-toxicities-an-emerging-hypothesis-for-neuropathy-and-gastrointestinal-toxicity/) - Abstract: Regimen-related toxicities remain a priority concern within the field of supportive care in cancer. Despite this, many forms of toxicity are under reported and consequently poorly characterised. Although there have been significant improvements in our understanding of regimen-related toxicities, symptom management continues to occur independently raising concerns such as drug interactions and the tendency
- [Could the Biological Robustness of Low Level Laser Therapy (Photobiomodulation) Impact its Use in the Management of Mucositis in Head and Neck Cancer Patients](https://biomodels.com/publication/could-the-biological-robustness-of-low-level-laser-therapy-photobiomodulation-impact-its-use-in-the-management-of-mucositis-in-head-and-neck-cancer-patients/) - Abstract: Low level laser therapy (LLLT) has been noted to be effective in mitigating the development of oral mucositis among patients being treated with chemoradiation for cancers of the head and neck. To explain the biological basis for this observation we performed a comprehensive literature search. Our investigation identified a substantial number of LLLT-activated pathways
- [Serum Amyloid P Ameliorates Radiation-Induced Oral Mucositis and Fibrosis](https://biomodels.com/publication/serum-amyloid-p-ameliorates-radiation-induced-oral-mucositis-and-fibrosis/) - Abstract: Purpose: To evaluate the effect of the anti-fibrotic protein serum amyloid P (SAP) on radiation-induced oral mucositis (OM) and fibrosis in a hamster cheek-pouch model. Experimental Design: Hamsters received a single dose of radiation (40 Gy) to the left everted cheek pouch to induce significant OM. The protective therapeutic potential of SAP was evaluated
- [A Clinically Translatable Mouse Model for Chemotherapy-Related Fatigue](https://biomodels.com/publication/a-clinically-translatable-mouse-model-for-chemotherapy-related-fatigue/) - Abstract: Fatigue is a debilitating and pervasive complication of cancer and cancer care. Clinical research investigating potential therapies is hindered by variability in patient histories, different metrics for measuring fatigue, and environmental factors that may affect fatigue. The purpose of this study was to establish an animal model of chemotherapy-related fatigue. Female HSD:ICR mice were
- [Local and Systematic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation](https://biomodels.com/publication/local-and-systematic-pathogenesis-and-consequences-of-regimen-induced-inflammatory-responses-in-patients-with-head-and-neck-cancer-receiving-chemoradiation/) - Abstract: Treatment-related toxicities are common among patients with head and neck cancer, leading to poor clinical outcomes, reduced quality of life, and increased use of healthcare resources. Over the last decade, much has been learned about the pathogenesis of cancer regimen-related toxicities. Historically, toxicities were separated into those associated with tissue injury and those with
- [Mechanisms of Cellular Fibrosis Associated with Cancer Regimen-Related Toxicities](https://biomodels.com/publication/mechanisms-of-cellular-fibrosis-associated-with-cancer-regimen-related-toxicities/) - Abstract: Fibrosis is a common, persistent and potentially debilitating complication of chemotherapy and radiation regimens used for the treatment of cancer. The molecular mechanisms underlying fibrosis have been well studied and reveal overall processes that are largely ubiquitous. However, it is important to note that although the processes are similar, they result in cellular phenotypes
- [Could the PI3K Canonical Pathway Be A Common Link Between Chronic Inflammatory Conditions and Oral Carcinogenesis?](https://biomodels.com/publication/could-the-pi3k-canonical-pathway-be-a-common-link-between-chronic-inflammatory-conditions-and-oral-carcinogenesis/) - Abstract: The association between chronic inflammatory disorders and oral carcinogenesis has been both a source of interest and contention. Based upon its central importance in oral carcinogenesis, the finding that the PI3k/Akt/mTOR pathway is activated in oral lichen planus, chronic graft-versus-host disease, and chronic oral candidiasis suggests that it may provide a link between benign
- [Gene Expression Changes in Peripheral Blood Cells Provide Insight into the Biological Mechanisms Associated with Regimen-Related Toxicities in Patients being treated for Head and Neck Cancers](https://biomodels.com/publication/gene-expression-changes-in-peripheral-blood-cells-provide-insight-into-the-biological-mechanisms-associated-with-regimen-related-toxicities-in-patients-being-treated-for-head-and-neck-cancers/) - Abstract: Patients treated with radiotherapy are prone to a constellation of local and systemic toxicities including mucositis, xerostomia, fatigue and anorexia. The biological complexities and similarities underlying the development of toxicities have recently been realized. Mucosal barrier injury is one of the best studied, and gene expression patterns, based on animal tissue samples, have added
- [Personalized Medicine for Mucositis: Bayesian Networks Identify Unique Gene Clusters which Predict the Response to Gamma-D-Glutamyl-L-Tryptophan (SCV-07) for the Attenuation of Chemoradiation-Induced Oral Mucositis](https://biomodels.com/publication/personalized-medicine-for-mucositis-bayesian-networks-identify-unique-gene-clusters-which-predict-the-response-to-gamma-d-glutamyl-l-tryptophan-scv-07-for-the-attenuation-of-chemoradiation-induced/) - Abstract: Gamma-d-glutamyl-l-tryptophan (SCV-07) demonstrated an overall efficacy signal in ameliorating oral mucositis (OM) in a clinical trial of head and neck cancer patients. However, not all SCV-07-treated subjects responded positively. Here we determined if specific gene clusters could discriminate between subjects who responded to SCV-07 and those who did not. Microarrays were done using peripheral
- [Bardoxolone Methyl Analogs RTA 405 and Dh404 are Well Tolerated and Exhibit Efficacy in Rodent Models of Type 2 Diabetes and Obesity](https://biomodels.com/publication/bardoxolone-methyl-analogs-rta-405-and-dh404-are-well-tolerated-and-exhibit-efficacy-in-rodent-models-of-type-2-diabetes-and-obesity/) - Abstract: Bardoxolone methyl and related triterpenoids are well tolerated and efficacious in numerous animal models potentially relevant to patients with Type 2 diabetes and chronic kidney disease. These agents enhance glucose control and regulate lipid accumulation in rodent models of diabetes and obesity, and improve renal function, reduce inflammation, and prevent structural injury in models
- [Prevention of Cartilage Degeneration and Restoration of Chondroprotection by Lubricin Tribosupplementation in the Rat Following Anterior Cruciate Ligament Transection](https://biomodels.com/publication/prevention-of-cartilage-degeneration-and-restoration-of-chondroprotection-by-lubricin-tribosupplementation-in-the-rat-following-anterior-cruciate-ligament-transection/) - Abstract: Objective: To investigate whether cartilage degeneration is prevented or minimized following intraarticular injections of lubricin derived from human synoviocytes in culture, recombinant human PRG4 (rhPRG4), or human synovial fluid (SF) in a rat model of anterior cruciate ligament (ACL) injury. Methods: Unilateral ACL transection (ACLT) was performed in Lewis rats (n = 45). Nine
- [Essential Role for Mast Cell Tryptase in Acute Experimental Colitis](https://biomodels.com/publication/essential-role-for-mast-cell-tryptase-in-acute-experimental-colitis/) - Abstract: Patients with inflammatory bowel disease (IBD) have increased numbers of human tryptase-β (hTryptase-β)-positive mast cells (MCs) in the gastrointestinal tract. The amino acid sequence of mouse mast cell protease (mMCP)-6 is most similar to that of hTryptase-β. We therefore hypothesized that this mMCP, or the related tryptase mMCP-7, might have a prominent proinflammatory role
- [AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease](https://biomodels.com/publication/avx-470-a-novel-oral-anti-tnf-antibody-with-therapeutic-potential-in-inflammatory-bowel-disease/) - Abstract: Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which is currently treated with injected monoclonal antibodies specific for tumor necrosis factor (TNF). We developed and characterized AVX-470, a novel polyclonal antibody specific for human TNF. We evaluated the oral activity of AVX-470m, a surrogate antibody specific for murine
- [Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management](https://biomodels.com/publication/oral-mucositis-in-head-and-neck-cancer-risk-biology-and-management/) - Abstract: Of the toxicities associated with conventional forms of treatment for head and neck cancers, probably none has such a consistent legacy as oral mucositis.1 Despite the fact that mucosal injury was noted as far back as Marie Curie’s first forays into therapeutic radiation, an effective intervention has yet to be developed. In addition to
- [Clinical Presentation and Management of MTOR Inhibitor-Associated Stomatitis](https://biomodels.com/publication/clinical-presentation-and-management-of-mtor-inhibitor-associated-stomatitis/) - Abstract: Anti-cancer agents that inhibit the mTOR pathway are associated with a number of unique toxicities, with one of the most significant and potentially dose-limiting being stomatitis. The objective of this study was to report the clinical features and management outcomes of a series of cancer patients who developed painful mTOR inhibitor-associated stomatitis (mIAS). Seventeen
- [Inflammation and Genetic Risk Indicators for Early Periodontitis in Adults](https://biomodels.com/publication/inflammation-and-genetic-risk-indicators-for-early-periodontitis-in-adults/) - Abstract: Background: This report is a further analysis of a study designed to determine clinical and microbial risk indicators for progressing periodontitis. Methods: One hundred ninety subjects who were periodontally healthy or had early signs of periodontitis (age range: 20 to 40 years) were monitored clinically at 6-month intervals followed by supragingival cleaning. At each
- [Pilot Study: Raman Spectroscopy in Differentiating Premalignant and Malignant Oral Lesions from Normal Mucosa and Benign Lesions in Humans](https://biomodels.com/publication/pilot-study-raman-spectroscopy-in-differentiating-premalignant-and-malignant-oral-lesions-from-normal-mucosa-and-benign-lesions-in-humans/) - Abstract: Background: Current practice for differentiating tissue lesions are based on histopathological criteria. This process is subject to error. The purpose of this study was to test whether an alternative, tissue-based molecular signatures Raman spectra could be used to differentiate premalignant and malignant lesions from normal mucosa or benign lesions. Methods: Eighteen treatment naïve subjects
- [A Novel Peptide to Treat Oral Mucositis Blocks Endothelial and Epithelial Cells Apoptosis](https://biomodels.com/publication/a-novel-peptide-to-treat-oral-mucositis-blocks-endothelial-and-epithelial-cells-apoptosis/) - Abstract: Purpose: No effective agents currently exist to treat oral mucositis (OM) in patients receiving chemoradiation for the treatment of head-ande-neck cancer. We identified a novel 21-amino acid peptide derived from antrum mucosal protein-18 that is cytoprotective, mitogenic, and motogenic in tissue culture and animal models of gastrointestinal epithelial cell injury. We examined whether administration
- [A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherap](https://biomodels.com/publication/a-randomized-double-blind-placebo-controlled-trial-of-misoprostol-for-oral-mucositis-secondary-to-high-dose-chemotherap/) - Abstract: Purpose: Misoprostol, a synthetic analog of prostaglandin E1, has anti-inflammatory and mucosa-protecting properties. The objective of this study was to evaluate the efficacy of misoprostol oral rinse in reducing the severity of oral mucosal injury caused by high-dose chemotherapy. Methods: The study used a randomized, double-blind, placebo-controlled, parallel-group design. Oncology patients receiving myeloablative high-dose
- [Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues](https://biomodels.com/publication/salen-mn-complexes-mitigate-radiation-injury-in-normal-tissues/) - Abstract: Salen Mn complexes, including EUK-134, EUK-189 and a newer cyclized analog EUK-207, are synthetic SOD/catalase mimetics that have beneficial effects in many models of oxidative stress. As oxidative stress is implicated in some forms of delayed radiation injury, we are investigating whether these compounds can mitigate injury to normal tissues caused by ionizing radiation.
- [Role of AMP-18 in Oral Mucositis](https://biomodels.com/publication/role-of-amp-18-in-oral-mucositis/) - Abstract: Oral mucositis (OM) is a devasting toxicity associated with cytotoxic cancer therapy. Antrum mucosal protein (AMP)-18 and a synthetic peptide surrogate, exhibit cell protective and mitogenic properties in in vitro and in vivo models of gastrointestinal epithelial cell injury. The mucosal barrier-protective effects may be mediated by AMP-18’s capacity to increase accumulation of specific
- [Emerging Evidence on the Pathobiology of Mucositis](https://biomodels.com/publication/emerging-evidence-on-the-pathobiology-of-mucositis/) - Abstract: Background: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods: Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December
- [The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhea, Oral Mucositis and Fatigue](https://biomodels.com/publication/the-economic-burden-of-toxicities-associated-with-cancer-treatment-review-of-the-literature-and-analysis-of-nausea-and-vomiting-diarrhea-oral-mucositis-and-fatigue/) - Abstract: Side effects or toxicities are frequent, undesirable companions of almost all forms of non-surgical cancer therapy. It is unusual for patients to complete treatment with radiation or chemotherapy without experiencing at least one form of therapy-associated tissue injury or systemic side effect. Often, toxicities do not occur as solitary events; rather, they result in
- [Phase 1b, Multicenter, Single Blinded, Placebo-Controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects with Locally Advanced Head and Neck Cancer Receiving Induction Chemotherapy](https://biomodels.com/publication/phase-1b-multicenter-single-blinded-placebo-controlled-sequential-dose-escalation-study-to-assess-the-safety-and-tolerability-of-topically-applied-ag013-in-subjects-with-locally-advanced-head-and/) - Abstract: Background: Oral mucositis (OM) is a significant toxicity of induction chemotherapy for locally advanced head and neck cancer (LAHNC). The safety and tolerability of AG013, an oral rinse containing recombinant Lactococcus lactis secreting mucosal protectant human trefoil factor 1 (hTFF1), was evaluated in a phase 1b study in LAHNC subjects who received induction with
- [SNP-Based Bayesian Networks Can Predict Oral Mucositis Risk in Autologous Stem Cell Transplant Recipients](https://biomodels.com/publication/snp-based-bayesian-networks-can-predict-oral-mucositis-risk-in-autologous-stem-cell-transplant-recipients/) - Abstract: Objective: Approximately 40% of patients receiving conditioning chemotherapy prior to autologous hematopoietic stem cell transplants (aHSCT) develop severe oral mucositis (SOM). Aside from disabling pain, ulcerative lesions associated with SOM predispose to poor health and economic outcomes. Our objective was to develop a probabilistic graphical model in which a cluster of single-nucleotide polymorphisms (SNPs)
- [Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy](https://biomodels.com/publication/oral-mucositis-due-to-high-dose-chemotherapy-and-or-head-and-neck-radiation-therapy/) - Abstract: Oral mucositis is a common side-effect associated with conventional cancer therapy and has also recently been reported in association with newly emerging cancer therapies. It is characterized as an inflammation of the oral mucous membranes accompanied by many complex mucosal and submucosal changes. Ulcerative oral mucositis can cause significant oral pain, impair nutritional intake,
- [The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies](https://biomodels.com/publication/the-broadening-scope-of-oral-mucositis-and-oral-ulcerative-mucosal-toxicities-of-anticancer-therapies/) - Abstract: Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint
- [A review of Oral Toxicity Associated with MTOR Inhibitor Therapy in Cancer Patients](https://biomodels.com/publication/a-review-of-oral-toxicity-associated-with-mtor-inhibitor-therapy-in-cancer-patients/) - Abstract: Aphthous-like stomatitis has been identified as one of the most common dose-limiting toxicities associated with mTOR inhibitor therapy in cancer patients. The objective of this study was to summarize the cumulative oral toxicities associated with mTOR inhibitors in published oncology trials with respect to dose, schedule, and need for dose modifications. A review of
- [Oral Ulcers in Patients with Advanced Breast Cancer Receiving Everolimus: A Case Series Report on Clinical Presentation and Management](https://biomodels.com/publication/oral-ulcers-in-patients-with-advanced-breast-cancer-receiving-everolimus-a-case-series-report-on-clinical-presentation-and-management/) - Abstract: Objective: We report the clinical features and management outcomes in 7 patients with everolimus-related stomatitis. Study Design: Fifteen women with hormone-receptor-positive advanced breast cancer receiving everolimus combined with exemestane were prospectively evaluated to assess the development of stomatitis. Oral ulcers were diagnosed based on established criteria. Results: Seven patients developed stomatitis (46.6%). All patients
- [Strategies to mitigate the toxicity of cancer therapeutics](https://biomodels.com/publication/strategies-to-mitigate-the-toxicity-of-cancer-therapeutics/) - Abstract Cancer therapeutics are dynamically evolving, and include traditional chemotherapy and hormone therapy, as well as more recently developed treatment modalities, such as tyrosine kinase inhibitors, monoclonal antibodies and the revolutionary approach based on immune checkpoint inhibition. These regimens are unfortunately not free of adverse events, and patients with cancer are a susceptible population experiencing
- [Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer](https://biomodels.com/publication/phase-iib-randomized-double-blind-trial-of-gc4419-versus-placebo-to-reduce-severe-oral-mucositis-due-to-concurrent-radiotherapy-and-cisplatin-for-head-and-neck-cancer/) - Abstract: Purpose: Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419, a superoxide dismutase mimetic, with placebo to reduce the duration, incidence, and severity of severe OM (SOM).
- [Oral lichen planus: comparative efficacy and treatment costs-a systematic review](https://biomodels.com/publication/oral-lichen-planus-comparative-efficacy-and-treatment-costs-a-systematic-review/) - Abstract: Objective: To compare the reported efficacy and costs of available interventions used for the management of oral lichen planus (OLP). Materials and methods: A systematic literature search was performed from database inception until March 2021 in MEDLINE via PubMed and the Cochrane library following PRISMA guidelines. Only randomized controlled trials (RCT) comparing an active
- [Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022](https://biomodels.com/publication/photobiomodulation-therapy-in-management-of-cancer-therapy-induced-side-effects-walt-position-paper-2022/) - Abstract: Disclaimer: This article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This
- [Treatment for Oral Mucositis-Current Options and an Update of Small Molecules Under Development](https://biomodels.com/publication/treatment-for-oral-mucositis-current-options-and-an-update-of-small-molecules-under-development/) - Abstract: Despite its history as one of the most impactful toxicities associated with cytotoxic cancer therapy, oral mucositis (OM) remains an unmet clinical need which affects hundreds of thousands of patients. Descriptions of its complex pathogenesis have provided mechanistic targets which are being exploited to develop an effective therapeutic intervention. Favorable results of recently completed
- [Evolution of predictive risk factor analysis for chemotherapy-related toxicity](https://biomodels.com/publication/evolution-of-predictive-risk-factor-analysis-for-chemotherapy-related-toxicity/) - Abstract: The causes of variation in toxicity to the same treatment regimen among seemingly similar patients remain largely unknown. There was tremendous optimism that the patient's germline genome would be strongly predictive of treatment-related toxicity and could be used to personalize treatment and improve therapeutic outcomes. However, there has been limited success in discovering robust
- [Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors](https://biomodels.com/publication/oral-manifestations-of-immune-related-adverse-events-in-cancer-patients-treated-with-immune-checkpoint-inhibitors/) - Abstract: Immunotherapy with immune checkpoint inhibitors (ICIs) has transformed cancer treatment over the past decade, improving survival rates in numerous advanced cancers. Immune-related adverse events (irAEs) are common and can affect any organ system, with many of these toxicities being well-characterized with clear grading criteria and management approaches. There has been less emphasis on oral
- [Avasopasem for the treatment of radiotherapy-induced severe oral mucositis](https://biomodels.com/publication/avasopasem-for-the-treatment-of-radiotherapy-induced-severe-oral-mucositis/) - Abstract: Introduction: Oral mucositis (OM) remains a significant, highly symptomatic, disruptive side effect of radiation and concomitant chemoradiation therapy used for the treatment of squamous cell cancers of the head and neck. Despite its clinical and economic burden, implementation of an effective intervention has been elusive. Areas covered: Increased understanding of the complexity of the
- [The pathogenesis of mucositis: updated perspectives and emerging targets](https://biomodels.com/publication/the-pathogenesis-of-mucositis-updated-perspectives-and-emerging-targets/) - Abstract: Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel therapeutic approaches and distils this to summary perspectives and recommendations. Reviewers assessed 164 articles published between January 2011 and June 2016
- [Superoxide Dismutase as an Intervention for Radiation Therapy-Associated Toxicities: Review and Profile of Avasopasem Manganese as a Treatment Option for Radiation-Induced Mucositis](https://biomodels.com/publication/superoxide-dismutase-as-an-intervention-for-radiation-therapy-associated-toxicities-review-and-profile-of-avasopasem-manganese-as-a-treatment-option-for-radiation-induced-mucositis/) - Abstract: Toxicities associated with radiation therapy are common, symptomatically devastating, and costly. The best chance to effectively mitigate radiation-associated normal tissue side effects are interventions aimed at disrupting the biological cascade, which is the basis for toxicity development, while simultaneously not reducing the beneficial impact of radiation on tumor. Oxidative stress is a key initiator
- [Radiotherapy-induced severe oral mucositis: pharmacotherapies in recent and current clinical trials](https://biomodels.com/publication/radiotherapy-induced-severe-oral-mucositis-pharmacotherapies-in-recent-and-current-clinical-trials/) - Abstract: Introduction: Oral mucositis (OM) is among the most common, damaging side effects of head and neck radiation therapy and may interfere with patients' ability to comply with optimal treatment. Areas covered: The increasing unmet clinical need, recent clinical trial successes, and the commercial potential have catalyzed interest in the development of effective intervention for
- [Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider](https://biomodels.com/publication/immune-checkpoint-inhibitors-in-cancer-therapy-review-of-orofacial-adverse-events-and-role-of-the-oral-healthcare-provider/) - Abstract: Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid,
- [A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment](https://biomodels.com/publication/a-hypothesis-for-the-pathogenesis-of-radiation-induced-oral-mucositis-when-biological-challenges-exceed-physiologic-protective-mechanisms-implications-for-pharmacological-prevention-and-treatment/) - Abstract: Oral mucositis (OM) remains a significant unmet need for patients being treated with standard concomitant chemoradiation (CRT) regimens for head and neck cancers (HNC). OM's pathogenesis is complex and includes both direct and indirect damage pathways. In this paper, the field is reviewed with emphasis on the initiating and sustaining role of oxidative stress
- [Psoriasis and oral health in adult United States population: a cross-sectional study](https://biomodels.com/publication/psoriasis-and-oral-health-in-adult-united-states-population-a-cross-sectional-study/) - Abstract: Objectives: To detect the association between psoriasis as an exposure and oral health conditions as outcomes represented by periodontal and dentition status. This was addressed by analysis of a large number of adults in the United States. Methods: By using The National Health and Nutrition Examination Survey datasets from 2009 to 2014, we performed
- [GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling](https://biomodels.com/publication/gm-1111-reduces-radiation-induced-oral-mucositis-in-mice-by-targeting-pattern-recognition-receptor-mediated-inflammatory-signaling/) - Abstract: Purpose: Oral mucositis (OM) is a common, painful side effect of radiation therapy used for the treatment of head and neck cancer (HNC). Activation of the innate immune system upon irradiation has been identified as a key precipitating event of OM. To better understand OM's pathogenesis, we studied pattern recognition receptors (PRRs) and their
- [Monte Carlo based dosimetry of extraoral photobiomodulation for prevention of oral mucositis](https://biomodels.com/publication/monte-carlo-based-dosimetry-of-extraoral-photobiomodulation-for-prevention-of-oral-mucositis/) - Abstract: Photobiomodulation therapy (PBMT) is recommended for prevention and treatment of oral mucositis, a painful condition that occurs in cancer patients. Intraoral PBMT is limited to treating distal oral mucosa and oropharynx. Extraoral PBMT may provide a more efficient intervention. The goal of this study was to develop a clinically viable protocol for extraoral PBMT.
- [Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019](https://biomodels.com/publication/oral-side-effects-of-immune-checkpoint-inhibitor-therapy-icit-an-analysis-of-4683-patients-receiving-icit-for-malignancies-at-massachusetts-general-hospital-brigham-womens-hospital-and-the-da/) - Abstract: Background: Immune checkpoint inhibitors (ICIs) are increasingly accepted as a treatment option for several cancers. Although various systemic immune-related adverse events (irAEs) have been characterized, the effect of ICIs on the oral cavity and contiguous structures is still poorly understood. Methods: Electronic medical records of 4683 patients in the Mass General Brigham Registered Patient
- [PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy](https://biomodels.com/publication/prevlar-phase-2a-randomized-trial-to-assess-the-safety-and-efficacy-of-rrx-001-in-the-attenuation-of-oral-mucositis-in-patients-receiving-head-and-neck-chemoradiotherapy/) - Abstract: Purpose: No Food and Drug Administration-approved intervention exists for oral mucositis (OM) from chemoradiotherapy (CRT) used to treat head and neck cancers. RRx-001 is a hypoxia-activated, cysteine-directed molecule that affects key pathways involved in OM pathogenesis. This phase 2a, multi-institutional trial was designed to assess the safety and feasibility of 3 schedules of a
- [Comparisons of Nonoral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles](https://biomodels.com/publication/comparisons-of-nonoral-immune-related-adverse-events-among-patients-with-cancer-with-different-oral-toxicity-profiles/) - Abstract: Objectives: Immune-related adverse events (irAEs) are common. Oral irAEs tend to cluster in patients who experience concurrent toxicities. We aimed to characterize the frequency and trajectory of nonoral irAEs in patients who developed oral irAEs, assess their relationship with nonoral irAEs, and compare those characteristics with patients without oral irAEs. Methods: A retrospective chart
- [Differential associations of rheumatoid arthritis and periodontitis or tooth loss: A cross-sectional study](https://biomodels.com/publication/differential-associations-of-rheumatoid-arthritis-and-periodontitis-or-tooth-loss-a-cross-sectional-study/) - Abstract: Aim: To study the association between periodontitis, tooth loss, and rheumatoid arthritis (RA) by using a large national dataset. Materials and methods: An observational cross-sectional study was performed using the National Health and Nutrition Examination Survey cycles (2009-2014). RA status was detected using a questionnaire. Periodontal status was assigned on the basis of the
- [Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2-functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer.](https://biomodels.com/publication/leveraging-gwas-data-derived-from-a-large-cooperative-group-trial-to-assess-the-risk-of-taxane-induced-peripheral-neuropathy-tipn-in-patients-being-treated-for-breast-cancer-part-2-functional-impli/) - Abstract: Introduction: Using GWAS data derived from a large collaborative trial (ECOG-5103), we identified a cluster of 267 SNPs which predicted CIPN in treatment-naive patients as reported in Part 1 of this study. To assess the functional and pathological implications of this set, we identified collective gene signatures were and evaluated the informational value of
- [Application of big data analyses to compare the impact of oral and gastrointestinal mucositis on risks and outcomes of febrile neutropenia and septicemia among patients hospitalized for the treatment of leukemia or multiple myeloma](https://biomodels.com/publication/application-of-big-data-analyses-to-compare-the-impact-of-oral-and-gastrointestinal-mucositis-on-risks-and-outcomes-of-febrile-neutropenia-and-septicemia-among-patients-hospitalized-for-the-treatment/) - Abstract: Purpose: Oral ulcerative mucositis (UM) and gastrointestinal mucositis (GIM) have been associated with increased likelihood of systemic infection (bacteremia and sepsis) in patients being treated for hematological malignancies. To better define and contrast differences between UM and GIM, we utilized the United States 2017 National Inpatient Sample and analyzed patients hospitalized for the treatment
- [Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial](https://biomodels.com/publication/identification-of-a-snp-cluster-associated-with-taxane-induced-peripheral-neuropathy-risk-in-patients-being-treated-for-breast-cancer-using-gwas-data-derived-from-a-large-cooperative-group-trial/) - Abstract: Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity of taxanes for which there is no effective intervention. Genomic CIPN risk determination has yielded promising, but inconsistent results. The present study assessed the utility of a collective SNP cluster identified using novel analytics to describe taxane-associated CIPN risk. Methods: We analyzed GWAS data derived
- [Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers](https://biomodels.com/publication/concordance-of-the-who-rtog-and-ctcae-v4-0-grading-scales-for-the-evaluation-of-oral-mucositis-associated-with-chemoradiation-therapy-for-the-treatment-of-oral-and-oropharyngeal-cancers/) - Abstract: Background: The ability to consistently and accurately assess oral mucositis (OM) is critical to descriptions of its incidence and severity and in evaluating the effectiveness of potential interventions. The lack of a single grading scale compounds outcome interpretation. Consequently, we assessed the concordance of three of the most commonly used OM grading criteria (World
- [The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis](https://biomodels.com/publication/the-path-to-an-evidence-based-treatment-protocol-for-extraoral-photobiomodulation-therapy-for-the-prevention-of-oral-mucositis/) - Abstract: Oral Mucositis is a painful complication of hematopoietic stem cell transplantation for which photobiomodulation therapy (PBMT) is a safe and effective intervention. Extraoral delivery of PBMT has clinical advantages over intraoral delivery but requires additional dosimetric considerations due to the external tissue layers through which the light must propagate before reaching the oral mucosa.
- [Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm](https://biomodels.com/publication/genomic-risk-prediction-of-aromatase-inhibitor-related-arthralgia-in-patients-with-breast-cancer-using-a-novel-machine-learning-algorithm/) - Abstract: Many breast cancer (BC) patients treated with aromatase inhibitors (AIs) develop aromatase inhibitor-related arthralgia (AIA). Candidate gene studies to identify AIA risk are limited in scope. We evaluated the potential of a novel analytic algorithm (NAA) to predict AIA using germline single nucleotide polymorphisms (SNP) data obtained before treatment initiation. Systematic chart review of
- [New Thoughts on the Initiation of Mucositis](https://biomodels.com/publication/new-thoughts-on-the-initiation-of-mucositis/) - Abstract: It has been slightly more than a decade since the classic mechanistic paradigm that defined the pathogenesis of mucositis was revised. A five-stage sequence of linked biological events forms the basis for our current understanding of how regimen-related mucosal injury occurs. The first stage is the initiation phase, although the gateway to toxicity has
- [AG013, a Mouth Rinse Formulation of Lactococcus lactis Secreting Human Trefoil Factor 1, provides a Safe and Efficacious Therapeutic Tool for Treating Oral Mucositis](https://biomodels.com/publication/ag013-a-mouth-rinse-formulation-of-lactococcus-lactis-secreting-human-trefoil-factor-1-provides-a-safe-and-efficacious-therapeutic-tool-for-treating-oral-mucositis/) - Abstract: Non-clinical studies, focusing on the pharmacodynamics (PD), pharmacokinetics (PK) and safety pharmacology of genetically modified Lactococcus lactis (L. lactis) bacteria, engineered to secrete human Trefoil Factor 1 (hTFF1), were performed to provide proof-of-concept for the treatment of oral mucositis (OM) patients. L. lactis strain sAGX0085 was constructed by stably inserting an htff1 expression cassette
- [Mucositis: The Impact, Biology and Therapeutic Opportunities of Oral Mucositis](https://biomodels.com/publication/mucositis-the-impact-biology-and-therapeutic-opportunities-of-oral-mucositis/) - Abstract: The history of mucositis is as old as radiation- and chemotherapy. Despite being regularly reported and documented as one of the worst side effects of cancer therapy, relatively little was appreciated about the complexities of mucositis' pathogenesis until relatively recently. More frustrating for patients and clinicians, no effective treatment existed. Fortunately, the situation is
- [Personalizing Supportive Care: Pharmacogenomics and Risk Prediction](https://biomodels.com/publication/personalizing-supportive-care-pharmacogenomics-and-risk-prediction/) - Abstract: The importance of treatment-related side effects in impeding effective cancer therapy was recognized in the recently articulated “cancer moonshot” initiative. Regimen-related toxicities impact the overall success of treatment outcomes—in some sense, a tail capable of wagging the dog. To truly impact the tolerability of treatment, effective, personalized, biologically-based prevention of side effects is more
- [A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis](https://biomodels.com/publication/a-novel-peptide-for-simultaneously-enhanced-treatment-of-head-and-neck-cancer-and-mitigation-of-oral-mucositis/) - Abstract: We have characterized a novel 21 amino acid-peptide derived from Antrum Mucosal Protein (AMP)-18 that mediates growth promotion of cultured normal epithelial cells and mitigates radiation-induced oral mucositis in animal models, while suppressing in vitro function of cancer cells. The objective of this study was to evaluate these dual potential therapeutic effects of AMP
- [Treatment-Related Gastrointestinal Toxicities and Advanced Colorectal or Pancreatic Cancer: A Critical Update](https://biomodels.com/publication/treatment-related-gastrointestinal-toxicities-and-advanced-colorectal-or-pancreatic-cancer-a-critical-update/) - Abstract: Gastrointestinal toxicities (GIT), including oral mucositis, nausea and vomiting, and diarrhea, are common side effects of chemotherapy and targeted agents in patients with advanced colorectal cancer and pancreatic cancer. Being often underreported, it is still difficult to precisely establish their burden in terms of both patient’s quality of life and cancer care costs. Moreover,
- [Design of Biomedical Robots for Phenotype Prediction Problems](https://biomodels.com/publication/design-of-biomedical-robots-for-phenotype-prediction-problems/) - Abstract: Genomics has been used with varying degrees of success in the context of drug discovery and in defining mechanisms of action for diseases like cancer and neurodegenerative and rare diseases in the quest for orphan drugs. To improve its utility, accuracy, and cost-effectiveness optimization of analytical methods, especially those that translate to clinically relevant

## News

- [𝗪𝗵𝗼 𝗶𝘀 𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀?](https://biomodels.com/news/𝗪𝗵𝗼-𝗶𝘀-𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀/) - 𝗜𝗻 𝘀𝗵𝗼𝗿𝘁: 𝗪𝗵𝗼 𝗶𝘀 𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀, 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝗱𝗼 𝘄𝗲 𝗱𝗼? We're a Boston-based preclinical CRO that helps biotechnology and pharmaceutical companies answer one critical question before moving into the clinic: 𝗗𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘄𝗼𝗿𝗸, 𝗮𝗻𝗱 𝗶𝘀 𝗶𝘁 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝗺𝗼𝘃𝗲 𝘁𝗼𝘄𝗮𝗿𝗱 𝘁𝗵𝗲 𝗰𝗹𝗶𝗻𝗶𝗰? We design and execute predictive, translational, non-GLP efficacy studies in mice, rats,
- [Maximizing Translational Impact: Behavioral Testing in Preclinical Disease Models](https://biomodels.com/news/maximizing-translational-impact-behavioral-testing-in-preclinical-disease-models/) - Join McKayla Nicol, Ph.D., scientist at BioModels, for an engaging live webinar titled "𝗠𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: 𝗕𝗲𝗵𝗮𝘃𝗶𝗼𝗿𝗮𝗹 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗱𝗲𝗹𝘀". 📅 𝗗𝗮𝘁𝗲: Tuesday, March 31 🕚 𝗧𝗶𝗺𝗲: 11:00AM EST 🔗 Click here to view webinar! Learn how to select and implement preclinical behavioral assays that generate clinically relevant, translational data. 𝙴̲𝚡̲𝚊̲𝚖̲𝚙̲𝚕̲𝚎̲𝚜̲ ̲𝚒̲𝚗̲𝚌̲𝚕̲𝚞̲𝚍̲𝚎̲:̲ • 𝗠𝗼𝘁𝗼𝗿
- [PK/PD - Gene Therapy](https://biomodels.com/news/pk-pd-gene-therapy/) - BioModels is well known for advanced in vivo efficacy studies across a range of disease indications. In addition, we offer straightforward, high-quality PK/PD support for gene therapy and biologic programs. Our PK/PD capabilities include: In vivo and ex vivo imaging Biodistribution assessment Quantification of tagged proteins, cells, or compounds Immunohistochemistry (IHC) for tissue-level insights These
- [Beyond Inflammation: Understanding Fibrosis in Colitis Through Preclinical Models](https://biomodels.com/news/beyond-inflammation-understanding-fibrosis-in-colitis-through-preclinical-models/) - Two experts in the preclinical space, BioModels and DTR Labs, are teaming up to present an upcoming webinar titled "Beyond Inflammation: Understanding Fibrosis in Colitis Through Preclinical Models". 📅 Date: October 30th 🕚 Time: 11:00AM EST 🔗 Click here to view webinar! During this session, Drs. Caitlin Parello and Jessica Durrant will discuss: The clinical background of fibrosis in IBD Key
- [Advancing Preclinical Research with Behavioral & Functional Assessments](https://biomodels.com/news/advancing-preclinical-research-with-behavioral-functional-assessments/) - At BioModels, we know how important it is to have reliable data you can trust. Behavioral and functional assessments are powerful tools to uncover insights in preclinical models from early safety to complex neurodegenerative disease studies. Our team is here to work alongside you, bringing expertise in evaluating activity, motor function, learning and memory, anxiety,
- [In-Life Monitoring](https://biomodels.com/news/in-life-monitoring/) - Effective data collection and monitoring of experimental animals are crucial for a successful preclinical program. BioModels provides a range of in-life monitoring options that allow for longitudinal assessment of study subjects over time. These assessments include: Body temperature evaluation IVIS imaging DEXA for body composition analysis HD video endoscopy and more! Do you want to
- [Chronic TNBS-Induced Colitis & Colon Fibrosis Model](https://biomodels.com/news/chronic-tnbs-induced-colitis-colon-fibrosis-model/) - As a preclinical CRO with extensive experience in IBD/Colitis modeling, BioModels is committed to continuously expanding our offerings and providing our clients with access to the most cutting-edge approaches. We're thrilled to share data on our Chronic TNBS-Induced Colitis Model, which allows for the assessment of critical IBD phenotypes, including not only inflammation but fibrosis as well. Standard
- [The BioModels Journey](https://biomodels.com/news/the-biomodels-journey/) - ​​​​​​​Are you "𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗼𝘂𝘁𝘀𝗶𝗱𝗲 𝘁𝗵𝗲 𝗯𝗼𝘅” for your next preclinical study? At BioModels, we understand that not every preclinical program has a clearly defined path to IND. Sometimes projects require creative scientific thinking and model development to deliver the solutions needed to advance your asset. 𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲𝘀 𝗶𝗻 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀. Whether
- [Check out BioModels Amylin Liver NASH (AMLN) Model!](https://biomodels.com/news/check-out-biomodels-amylin-liver-nash-amln-model/) - With an increasing need for translational preclinical NAFLD, NASH, and liver fibrosis models, BioModels is pleased to share our recent validation data from the amylin liver NASH (AMLN) model. This model recapitulates many features of human disease, including steatosis and fibrosis. BioModels is ready to help you assess your therapeutic for the treatment of this extremely
- [Acute GVHD (Major MHC Mismatch) Model!](https://biomodels.com/news/acute-gvhd-major-mhc-mismatch-model/) - Interested in evaluating your therapeutic in a preclinical model of GVHD? Assess your experimental materials for efficacy and mechanism of action in our established rodent models. BioModels' GVHD models allow you to evaluate the immunopathology of post-transplant disease in various organs such as skin, gut, liver, and lung. The BioModels team is experienced with multiple
- [IT vs SC Osmotic Pump Bleomycin-Induced Fibrosis Models](https://biomodels.com/news/it-vs-sc-osmotic-pump-bleomycin-induced-fibrosis-models/) - Are you interested in treating pulmonary fibrosis, but uncertain which preclinical model is the best fit? Fortunately, BioModels is here to help. We have experience with a variety of pulmonary fibrosis induction paradigms, including: Intratracheal Bleomycin-Induced SC Osmotic Pump Bleomycin-Induced Radiation-Induced Human in vitro Model of TGF-β-induced Fibrosis in Normal Human Lung Fibroblasts (NHLF) Today, we’re
- [Presentation at AAI 2024!](https://biomodels.com/news/presentation-at-aai-2024/) - BioModels exhibits and Dr. Caitlin Parello presents at the annual American Association of Immunologists meeting. Dr. Parello will present a poster and talk titled “Validation of a Microbiome Dependent Colitis Model via Fecal Microbial Transplant in Germ-Free IL-10 Deficient Mice”. Poster Details: May 4, 2024 | Board # B812 | 3:15pm-4:15pm CT Talk Details: May
- [Taconic Biosciences and Biomodels Establish Microbiome Initiative](https://biomodels.com/news/taconic-biosciences-and-biomodels-establish-microbiome-initiative/) - Seamless, Comprehensive Capabilities Eliminate Barriers to Microbiome Research Rensselaer, NY — April 26, 2022 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and
- [June 2022 Newsletter](https://biomodels.com/news/june-2022-newsletter/) - Link: June 2022 Newsletter_0.pdf (biomodels.com)
- [Taconic Biosciences and Biomodels Team up for a Webinar](https://biomodels.com/news/taconic-biosciences-and-biomodels-team-up-for-a-webinar/) - Biomodels and Taconic Biosciences team up to share more on our initiative (TBMI) and to present “Key Considerations When Planning a Gut Microbiome Study.” The gut microbiome plays a significant role in human health and disease. However, given the complexities of the microbiome, investigators aiming to contribute to this transformative space often lack easy access
- [May 2023 Newsletter](https://biomodels.com/news/may-2023-newsletter/) - Link: May 2023 Newsletter Final (biomodels.com)
- [Join our Webinar on IBD, GVHD and Pulmonary Disease](https://biomodels.com/news/join-our-webinar-on-ibd-gvhd-and-pulmonary-disease/) - Join Biomodels' Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of IBD, GVHD and pulmonary disease. When: April 4, 2024 at 11am ET Register here! Key Topics Include: Learn about translational and predictive animal models of Inflammatory Bowel Disease (IBD), Graft versus Host Disease (GVHD), and
- [Dr. Parello to Present at Microbiome 2022](https://biomodels.com/news/dr-parello-to-present-at-microbiome-2022/) - Biomodels attends and presents at the 7th Microbiome Movement Drug Development Summit, June 21-24, 2022. Dr. Caitlin Parello to present "Customized End to End Solutions to Explore the Microbiome in Preclinical Research" During the meeting we invite you to visit Biomodels to meet our team. If you prefer to schedule a time to connect in
- [September 2022 Microbiome Webinar](https://biomodels.com/news/september-2022-microbiome-webinar/) - Dr. Caitlin Parello to present "Customized End-to-End Solutions to Explore the Microbiome in Preclinical Research". September 27th, 2022 at 11:00AM EDT View Webinar Sponsored by: Biomodels LLC Description: The microbiome represents a novel and exciting therapeutic target, with a critical function in the maintenance of immune homeostais, and a dysfunctional microbiome is linked to a
- [Dr. Parello to Present at the Microbiome Movement Summit 2023](https://biomodels.com/news/dr-parello-to-present-at-the-microbiome-movement-summit-2023/) - Biomodels attends and Dr. Caitlin Parello presents at the 8th Microbiome Movement Drug Development Summit, June 29-30, 2023. Thursday (6/29) at 12pm EST Dr. Parello will present "Customized End to End Solutions to Explore the Microbiome in Preclinical Research" During the meeting we invite you to stop by Biomodels' booth to meet our team. If

## Capabilities

- [Cell and Mollecular Biology](https://biomodels.com/capabilities/cell-mollecular-biology/) - Cancer Cell Line Inventory MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) Cell Separation System (Miltenyi Biotec) RT-PCR
- [Administration Routes](https://biomodels.com/capabilities/administration-routes/) - Cancer Cell Line Inventory MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) Cell Separation System (Miltenyi Biotec) RT-PCR
- [Tissue Collection/ Histology/  Immunohistochemistry](https://biomodels.com/capabilities/tissue-collection-histology-immunohistochemistry/) - IVIS Lumini III Imaging System (Perkin Elmer) MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) HD Endoscopy (Karl Storz) FlexiVent™ Rodent Mechanical Ventilator (SCIREQ) X-Ray Radiation Source (Kimtron
- [In Life Monitoring](https://biomodels.com/capabilities/in-life-monitoring/) - IVIS Lumini III Imaging System (Perkin Elmer) MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) HD Endoscopy (Karl Storz)
- [Blood Analysis](https://biomodels.com/capabilities/blood-analysis/) - Laser Doppler Blood Flow Monitor (Oxford Optronix) TopScan Video Tracking Software (for behavioral testing) Running Wheels (for activity monitoring/circadian rhythm in mice) Metabolic Cages Behavior Assessment
- [Microscopy](https://biomodels.com/capabilities/microscopy/) - IVIS Lumini III Imaging System (Perkin Elmer) MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) HD Endoscopy (Karl Storz) FlexiVent™ Rodent Mechanical Ventilator (SCIREQ) X-Ray Radiation Source (Kimtron
- [Equipment](https://biomodels.com/capabilities/equipment/) - IVIS Lumini III Imaging System (Perkin Elmer) MACSQuant Analyzer for FACS analysis (Miltenyi Biotec) HD Endoscopy (Karl Storz) FlexiVent™ Rodent Mechanical Ventilator (SCIREQ) X-Ray Radiation Source (Kimtron

## Webinars

- [Maximizing Translational Impact: Behavioral Testing in Preclinical Disease Models](https://biomodels.com/webinar/maximizing-translational-impact-behavioral-testing-in-preclinical-disease-models/)
- [Beyond Inflammation: Understanding Fibrosis in Colitis Through Preclinical Models](https://biomodels.com/webinar/beyond-inflammation-understanding-fibrosis-in-colitis-through-preclinical-models/)
- [Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease](https://biomodels.com/webinar/preclinical-animal-models-of-ibd-gvhd-and-pulmonary-disease/)
- [Customized End-to-End Solutions to Explore the Microbiome in Preclinical Research](https://biomodels.com/webinar/customized-end-to-end-solutions-to-explore-the-microbiome-in-preclinical-research/)
- [Preclinical Mouse Models of Pulmonary Disease: Acute Lung Injury, Acute and Severe Asthma, and Pulmonary Fibrosis](https://biomodels.com/webinar/preclinical-mouse-models-of-pulmonary-disease-acute-lung-injury-acute-severe-asthma-pulmonary-fibrosis/)
- [Utilizing Gnotobiotic Mice to Understand the Role of the Microbiome in Murine Disease Models](https://biomodels.com/webinar/utilizing-gnotobiotic-mice-to-understand-the-role-of-the-microbiome-in-murine-disease-models/)
- [Current Preclinical Models in Oncology-Enhancing Predictivity for Translational Success](https://biomodels.com/webinar/current-preclinical-models-in-oncology-enhancing-predictivity-for-translational-success/)
- [Immunological Methods- Understanding and Enhancement of Preclinical Animal Models of Disease](https://biomodels.com/webinar/immunological-methods-understanding-and-enhancement-of-preclinical-animal-models-of-disease/)
- [Precision Medicine in Cancer Supportive Care](https://biomodels.com/webinar/precision-medicine-in-cancer-supportive-care/)
- [Leveraging New and Established Preclinical Oncology Models for Translational Success](https://biomodels.com/webinar/leveraging-new-and-established-preclinical-oncology-models-for-translational-success/)
- [Predictive Preclinical Animal Models of Pulmonary Disease: Acute and Severe Asthma, Pulmonary Fibrosis, Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)](https://biomodels.com/webinar/predictive-preclinical-animal-models-of-pulmonary-disease-acute-severe-asthma-pulmonary-fibrosis-acute-lung-injury-ali-acute-respiratory-distress-syndrome-ards/)
- [Clinically Relevant Animal Models of Inflammatory Bowel Disease: Utilizing Classical and Novel Approaches to Evaluate Potential Therapies](https://biomodels.com/webinar/clinically-relevant-animal-models-of-inflammatory-bowel-disease-utilizing-classical-and-novel-approaches-to-evaluate-potential-therapies/)
- [Novel Opportunities for the Development of Drugs and Biologics in Cancer Supportive Care](https://biomodels.com/webinar/novel-opportunities-for-the-development-of-drugs-and-biologics-in-cancer-supportive-care/)
- [Preclinical Models Designed for the Development of Treatment Strategies for Radiation-Induced Tissue Toxicities](https://biomodels.com/webinar/preclinical-models-designed-for-the-development-of-treatment-strategies-for-radiation-induced-tissue-toxicities/)
- [Immunological Methods to Enhance Translatability of Preclinical Models of Graft-vs.-Host Disease and Inflammatory Bowel Disease](https://biomodels.com/webinar/immunological-methods-to-enhance-translatability-of-preclinical-models-of-graft-vs-host-disease-and-inflammatory-bowel-disease/)
- [Animal Modeling of Disease States with a Microbiome Component](https://biomodels.com/webinar/animal-modeling-of-disease-states-with-a-microbiome-component/)
- [Tailored to Translate: Custom Preclinical Models for Advancing Diverse Therapeutic Strategies in Oncology](https://biomodels.com/webinar/tailored-to-translate-custom-preclinical-models-for-advancing-diverse-therapeutic-strategies-in-oncology/)
- [Innovation in Translational Rodent Models of Colitis](https://biomodels.com/webinar/innovation-in-translational-rodent-models-of-colitis/)
- [Clinically Relevant Animal Models of Fibrosis: Utilizing Classical and Novel Approaches to Evaluate Potential Therapies](https://biomodels.com/webinar/clinically-relevant-animal-models-of-fibrosis-utilizing-classical-and-novel-approaches-to-evaluate-potential-therapies/)
- [Preclinical Models of Immune-Mediated Diseases to Enable Development of Novel Immunomodulatory Therapies](https://biomodels.com/webinar/preclinical-models-of-immune-mediated-diseases-to-enable-development-of-novel-immunomodulatory-therapies/)
- [Preclinical Animal Models in Cancer Supportive Care](https://biomodels.com/webinar/preclinical-animal-models-in-cancer-supportive-care/)

## Categories

- [Uncategorized](https://biomodels.com/category/uncategorized/)
- [Inflammatory & Immune Medieated Diseases](https://biomodels.com/category/inflammatory-immune-medieated-diseases/)

## Categories

- [Cancer Supportive Care](https://biomodels.com/?p_cat=cancer-supportive-care)
- [Genomics](https://biomodels.com/?p_cat=genomics)
- [Oncology](https://biomodels.com/?p_cat=oncology)
- [Inflammatory Diseases](https://biomodels.com/?p_cat=inflammatory-diseases)
- [All](https://biomodels.com/?p_cat=all)
- [Fibrosis](https://biomodels.com/?p_cat=fibrosis)
- [Metabolic Disease](https://biomodels.com/?p_cat=metabolic-disease)
- [Radiation Countermeasures](https://biomodels.com/?p_cat=radiation-countermeasures)